You are here

ABT-494

Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug

BioPharma Dive

Wed, 12/20/17 - 11:42 am

rheumatoid arthritis

AbbVie keen on JAK inhibitor despite safety concerns

BioPharma Dive

Tue, 09/12/17 - 04:22 pm

rheumatoid arthritis

AbbVie reports two patient deaths in rheumatoid arthritis study

Yahoo/Reuters

Mon, 09/11/17 - 09:25 am

clinical trials

rheumatoid arthritis

AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis

Endpoints

Thu, 09/7/17 - 09:46 am

atopic dermatitis

Gilead Takes Lead on Crohn's over AbbVie

Investopedia

Mon, 11/28/16 - 11:33 pm

Gilead Sciences

Crohn's Disease

How AbbVie Plans To Replace Humira

Seeking Alpha

Tue, 04/12/16 - 07:43 am

autoimmune disease

AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis

Yahoo

Fri, 01/8/16 - 09:49 am

rheumatoid arthritis

AbbVie dumps Galapagos' arthritis drug and presses on with its own

Fierce Biotech

Fri, 09/25/15 - 10:13 am

rheumatoid arthritis

AbbVie Has Some Excellent Entries In Rheumatoid Arthritis

Seeking Alpha

Fri, 01/2/15 - 07:35 pm

rheumatoid arthritis